Introduction: Despite abundant information on the negative impacts of smoking, more than 40 million adult Americans continue to smoke. The Affordable Care Act (ACA) requires tobacco cessation as a preventive service with no patient cost share for all FDA-approved cessation medications. Health plans have a vital role in supporting smoking cessation by managing medication access, but uncertainty remains on the gaps between smoking cessation requirements and what is actually occurring in practice. This study presents current cessation patterns, real-world drug costs and plan benefit design data, and estimates the 1-to 5-year pharmacy budget impact of providing ACA-required coverage for smoking cessation products to understand the fiscal impact to a US healthcare plan. Methods: A closed cohort budget impact model was developed in Microsoft Excel Ò to estimate current and projected costs for US payers (commercial, Medicare, Medicaid) covering smoking cessation medicines, with assumptions for coverage and smoking cessation product utilization based on current, real-world national and state-level trends for hypothetical commercial, Medicare, and Medicaid plans with 1 million covered lives. A Markov methodology with five health states captures quit attempt and relapse patterns. Results include the number of smokers attempting to quit, number of successful quitters, annual costs, and cost per-member per-month (PMPM). Results: The projected PMPM cost of providing coverage for smoking cessation medications is $0.10 for commercial, $0.06 for Medicare, and $0.07 for Medicaid plans, reflecting a low incremental PMPM impact of covering two attempts ranging from $0.01 for Medicaid to $0.02 for commercial and Medicare payers. Enhanced content To view enhanced content for this article go to www.medengine.com/Redeem/ E127F0604E77033C. Electronic supplementary material The online version of this article (
INTRODUCTION
Cigarette smoking is a serious public health concern and, despite ongoing educational efforts, it remains the leading preventable cause of death in the USA [1] .
Recent data from the Centers for Disease Control and Prevention and national cohort studies indicate that smoking is causally, or suspected causally, related to approximately 500,000 deaths each year [1] [2] [3] . Smoking is responsible for approximately 87% of all lung cancer deaths, 80-90% of chronic obstructive lung disease, and 32% of heart disease deaths [1] . In addition to the significant mortality burden, cigarette smoking exacts a striking financial burden, accounting for an estimated $133 to $176 billion in direct medical care costs, $151 billion in lost productivity from premature death, and almost $6 billion due to lost productivity from secondhand smoke exposure in the USA alone [1] . Despite this abundance of information on the negative health and economic impacts of smoking, more than 40 million adult Americans (15.1% of adults) continue to smoke cigarettes [4] .
Though the negative effects of smoking are considerable, smoking cessation has immediate and lasting impacts on smoker health outcomes as well as the trajectory of healthcare spend.
Smokers see benefits in improved circulation and lung function within 2 weeks to 3 months of cessation [5] . Also, within 1 year of cessation, smoking-related excess risk of coronary heart disease reduces to half that of a current smoker, and by 5 years, throat, mouth, esophageal, and bladder cancer risks are halved [5] . After 20 years, excess risks for pancreatic cancer, cardiovascular-related mortality, and female mortality are reduced to that of a never smoker [6] [7] [8] . The impact of cessation on morbidity and mortality can also have a large effect on healthcare spending. A recent study focusing on smoking and expenditures in the US concluded that a 10% relative drop in smoking in each state would result in an estimated $63 billion reduction (in 2012 US dollars) in healthcare costs the following year [9] .
Increasing access to smoking cessation tools and resources is integral in promoting smoking cessation, increasing quit rates, and reducing the burden of smoking. An estimated 70% of smokers want to quit smoking, 42.7% try to quit each year, and 30.8% use smoking cessation treatments [1, 10] . Unaided, the success rate is approximately 5% [10, 11] [13] . Therefore, it is not unexpected that tobacco cessation services were incorporated as a principle of the Patient Protection and Affordable Care Act (ACA; Pub L No. 111-148) [14] .
Under the ACA, tobacco cessation is included as a required preventive service with no patient cost share. [15] .
Health plans manage health benefits and medication access through their prescription formularies and product coverage and, therefore, play a vital role in supporting smoking cessation. A March 2015 study by the American Lung Association found that less than 20% of plan insurers were offering sufficient coverage and fewer than 50% listed the seven approved cessation medications on their formularies [16] . An August 2015 an update to that report found a dramatic increase in the availability of formularies and other documents highlighting coverage for smoking cessation and guidance for subscribers on coverage access for smoking cessation [17] .
However, uncertainty remains on the gaps between smoking cessation requirements and
what is actually occurring in practice. Further, health plans bear the fiscal burden for operationalizing ACA requirements. The true fiscal impact of adopting ACA requirements is dependent on a multitude of factors, ranging from current patient cost sharing practices to smoking cessation trends to the efficacy of cessation medications. In this study, we first gather data on current cessation patterns as well as real-world drug costs and plan benefit design data to articulate the current cost of providing access to smoking cessation medicines and to highlight the gaps between current coverage and ACA requirements. Next, we estimate the 1to 5-year pharmacy budget impact of providing ACA-required coverage for smoking cessation products to understand the fiscal impact to a US healthcare plan.
METHODS

Smoking Cessation Budget Impact Model Framework
A budget impact model was developed in
Microsoft Excel Ò to simulate current and projected costs for health plans covering cessation medicines. The model takes the perspective of a US healthcare payer, using nationally representative default scenarios developed for public (Medicare, Medicaid) and private (commercial) payers. The model leverages a market-based approach to estimate the pharmacy budget impact of providing ACA-required coverage for smoking cessation products. First, the model estimates the current (or baseline) annual budget for a health plan, with assumptions for coverage and smoking cessation product utilization based on current, real-world national and state-level trends. Next, a projected scenario is generated which adjusts the coverage parameters to reflect optimized ACA-required coverage. Finally, the budget impact of adopting the ACA-required smoking cessation coverage is the difference between the baseline (current world) and projected (ACA-required) estimates. Model results include the number of smokers attempting to quit with covered products, number of successful quitters, annual costs, and cost per-member per-month (PMPM). Please note that this article does not contain any new studies with human or animal subjects performed by any of the authors but is based on previously published literature.
To simulate patterns for quit attempts, smoking relapse, and cessation success, the model utilizes a Markov methodology with five health states and 6-month cycle lengths ( Fig. 1 ). To estimate the number of successful quitters, the model begins with the entire population of adult smokers. Among the population that attempts to quit, a portion will utilize pharmaceutical smoking cessation medications and the remaining will attempt to quit without aids.
Model Inputs
Data inputs in the model are populated with information from peer-reviewed literature, publicly available data sources, and the IMS National Prescription Audit TM (NPA) [18] . The model base-case estimates impact of offering ACA coverage for a hypothetical health plan with 1 million covered lives. A closed cohort model is used, where no smokers enter over time and smokers can only leave as a result of all-cause mortality [19] . This approach helps to isolate the impact of smoking cessation on a given population of smokers over time. Information on the age and gender distribution of the US population from the US census, national estimates for the prevalence of smoking, annual quit attempts, and the utilization of smoking cessation products are leveraged to isolate the population of smokers using smoking cessation products filled by a prescription that would be covered by their health plan [10, [20] [21] [22] . In the base case, the model assumes the same utilization of prescription cessation medications (7.4%), among the population using prescription and over the counter (OTC) medications, across age groups and payer types [18] .
The national commercial and Medicaid population inputs can be found in Table 1 . IniƟal QuiƩer: A tunnel state for smokers who have aƩempted to quit in the current year, and are currently absƟnent from smoking during the current cycle but who have not yet met the criteria for 'Successful QuiƩer'.
Starting with a hypothetical plan of 1 million
Successful QuiƩer:
Consists of iniƟal quiƩers who have abstained from smoking for the required length of Ɵme to meet the clinical definiƟon of success and who have not relapsed. The model assumes that a person becomes a 'Successful QuiƩer' aŌer being absƟnent from smoking for one full year.
Death:
Captures death due to all-cause mortality, based on age-and gender-adjusted rates from US life tables from the Centers for Disease Control and PrevenƟon [19] . [13] . Note that OTC NRTs are included to account for NRT therapies being dispensed by prescription and covered under the ACA, as captured in the IMS NPA data [18] .
Therefore, while the model only examines smokers utilizing prescription smoking cessation therapies, some OTC medicines are included if they were dispensed with a prescription.
Data on utilization and pricing of smoking cessation medications as well as patient cost share trends are based on IMS NPA data as of January 2016 [18] . Late relapse is used to estimate the number of former smokers who were successful quitters (e.g., have quit for 12 months) but then eventually relapse to account for a return to smoking after a period of initial success.
Published data supports the assumption that as the duration of time since quitting increases, relapse decreases. Therefore, an annual relapse rate of 6.3% based on previously published studies was utilized in the model [23, 24] .
Smoking cessation intervention efficacy is based on data drawn from a Cochrane systematic review [25] . Systematic reviews were used rather than head-to-head trials to maximize the number of treatments included in the model and to characterize a wide-ranging analysis of available efficacy data. The 12-month quit rate for placebo (9.3%) was based on a pooled analysis of 52-week continuous abstinence rates from two randomized controlled trials comparing varenicline, bupropion, and placebo [26] .
Efficacy information for unaided cessation (5.0%) was also collected to model cessation patterns for individuals trying to quit smoking without using any cessation medications [11] .
All smokers are eligible for quit attempts. The model also includes smokers who attempt to quit without smoking cessation pharmacotherapy to account for smokers who may successfully quit unaided and to accurately Table 2 National commercial inputs for product utilization and unit costs [18] model the relapse patterns and additional cessation attempts (with and without smoking cessation medications) for the entire group over the model time horizon. Results from the model represent outcomes only for smokers who attempt to quit using smoking cessation medications filled by prescription to estimate the pharmacy budget impact of smoking cessation coverage to a health plan. Table 3 highlights the efficacy rates of smoking cessation interventions.
Model Base Case
The inputs and assumptions used in the base-case scenario were chosen to compare the current smoking cessation intervention usage and average patient out of pocket costs and medication unit costs to a projected scenario where health plans follow ACA-required guidance for smoking cessation coverage. The Table 4 for details.
A change in benefit to cover two quit attempts per year increases the number of Utilization changes are likely to occur with the increased benefit under ACA because more patients may utilize smoking cessation therapy when the cost barrier is alleviated.
Even while taking into account these limitations, there are several important implications of this research worth noting.
Specific aspects of the ACA requirements are essential to ensuring success with cessation.
First, the elimination of cost sharing is foundational to providing access to effective medications and supporting potentially higher quit rates. This was observed in a Cochrane review comparing abstinence rates for individuals with and without full coverage programs. Specifically, the relative risk for abstinence at 6 months or more with full financial coverage compared to no coverage was 2.45 (95% confidence interval [CI]
1.17-5.12) [28] . There was also a positive effect of full financial interventions on the number of participants making a quit attempt (RR 1.11, 95% CI 1.04-1.32) and use of smoking cessation treatment [28] . Further, access to the full range of pharmacotherapy options can also achieve the goal of long-term abstinence [29] . The US Department of Health and Human Services clinical practice guidelines, as well as recommendations of the ACA, reinforce the importance of providing access to a full range of proven smoking cessation medications [13, 14] .
From a PMPM perspective, the net impact to a plan increases marginally over all scenarios from $0.01 (Medicaid) to $0.02 (commercial)
when the ACA guidelines are optimized.
However, these estimates still fall below the $0.10 to $0.40 PMPM range seen in previous budget impact models for smoking cessation medications [27] . Given the proven efficacy of pharmacotherapy for smoking cessation, near-term investment in supporting the ACA-required smoking cessation benefits may translate into a long-term return on investment in health and economic outcomes [30] .
Changes in healthcare spending are realized quickly after changes in smoking behavior [31] [32] [33] . Once patients stop smoking, immediate health benefits are realized and healthcare and societal costs decline [9] .
Therefore, health plan policies and benefits that determine and support smoking cessation are essential to help reduce healthcare costs.
CONCLUSION
This study provides real-world evidence-based information on utilization patterns for prescription smoking cessation products, national average cost, and patient cost sharing. This study also provides direct 
